You are here

Article Text

Article menu
Download PDFPDF
Review
Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers
  1. Ryan Yann Shern Keh1,2,
  2. Sachit Shah3,
  3. James B Lilleker2,4,
  4. Tim Lavin2,
  5. Jasper Morrow1,3,
  6. Aisling S Carr1,5,
  7. Michael P Lunn1,5
  1. 1 Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK
  2. 2 Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK
  3. 3 Lysholm Department of Neuroradiology, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK
  4. 4 Division of Musculoskeletal and Dermatological, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
  5. 5 Institute of Neurology, University College London, London, UK
  1. Correspondence to Dr Michael P Lunn; michaellunn{at}nhs.net

Abstract

In clinical neurology practice, there are few sensitive, specific and responsive serological biomarkers reflecting pathological processes affecting the peripheral nervous system. Instead, we rely on surrogate multimodality biomarkers for diagnosis and management. Correct use and interpretation of the available tests is essential to ensure that appropriate treatments are used and adjusted in a timely fashion. The incorrect application or interpretation of biomarkers can result in misdiagnosis and delays in appropriate treatment. Here, we discuss the uses and limitations of such biomarkers and discuss possible future developments.

  • NEUROPATHY
  • CLINICAL NEUROLOGY
  • NEUROPHYSIOLOGY
  • NEURORADIOLOGY

Data availability statement

Data sharing not applicable as no datasets generated and/or analysed for this study.

https://doi.org/10.1136/pn-2022-003438

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data sharing not applicable as no datasets generated and/or analysed for this study.

    View Full Text

    Footnotes

    • Twitter @mike_the_nerve

    • Collaborators N/A.

    • Contributors All authors were involved in conception, drafting and revision of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests No specific funding was received for this work. MPL, ASC and JM are supported by the National Institute for Health Research, University College London Hospitals NHS Foundation Trust and Biomedical Research Centre. RYSK is funded by GBS‐CIDP Foundation International.

    • Provenance and peer review Commissioned; externally peer reviewed by Simon Rinaldi, Oxford, UK.

    Linked Articles

    • Highlights from this issue
      Editors’ commentary
      Phil E M Smith Geraint N Fuller
      Practical Neurology 2022; 22 445-445 Published Online First: 30 Nov 2022. doi: 10.1136/pn-2022-003637

    Other content recommended for you